{
  "docId": "019de074-f95f-763f-9a80-be3b653e0df1",
  "docSlug": "502ed4e7545b260f09647399e486ae2c",
  "documentTitle": "Matinas BioPharma | Investor Presentation Deck | 28 slides",
  "authorId": "matinas-biopharma",
  "authorName": "Matinas BioPharma",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-05-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 13,
  "pageCount": 28,
  "prevPage": 12,
  "nextPage": 14,
  "slideType": "traction",
  "function": "show_traction",
  "density": "dense",
  "nDataPoints": 7,
  "notes": "The slide uses a process flow diagram to present five key clinical outcomes.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de074-f95f-763f-9a80-be3b653e0df1/13",
  "deckHref": "/decks/019de074-f95f-763f-9a80-be3b653e0df1",
  "deckJsonHref": "/decks/019de074-f95f-763f-9a80-be3b653e0df1.json",
  "deckAnchorHref": "/decks/019de074-f95f-763f-9a80-be3b653e0df1#slide-13",
  "components": [
    {
      "bbox": {
        "h": 0.35,
        "w": 0.88,
        "x": 0.06,
        "y": 0.3
      },
      "kind": "diagram",
      "text": "Five-step process flow showing clinical outcomes",
      "attrs": null,
      "subkind": "process",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "91e3d2a1-023f-427f-9dc7-8a6c3984fd25",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.9,
        "x": 0.05,
        "y": 0.72
      },
      "kind": "list",
      "text": "EFA for MAT2203 was 0.42 (95% CI 0.29 to 0.55); 97% for patients receiving MAT2203; 76% for patients receiving SOC; Over 10 weeks, patients showed no breakthrough infections; 98% for patients receiving MAT2203; 88% for patients receiving IV Ampho (SOC); Repeat dosing showed no renal toxicity; No discontinuations due to AEs",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "52307b2a-8846-40d1-8659-d1cdd9bf23b8",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.5,
        "x": 0.25,
        "y": 0.18
      },
      "kind": "title",
      "text": "EnACT Clinical Data VALIDATES the Use of the LNC Platform to Enable Oral Administration and Overcome Toxicity",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "60926eaa-fd45-4460-8f66-4110f6d2dccb",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.6,
        "x": 0.04,
        "y": 0.06
      },
      "kind": "title",
      "text": "EnACT : Cohort 2 Results (Validation of Efficacy and Safety)",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "45a8298c-867a-45aa-bd25-e66420bdd449",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "AIDA Model",
      "slug": "aida-model",
      "agent": "Storyteller",
      "layer": "slide",
      "matchId": "ac45efd6-2c9f-4077-9784-f03e47bbb026",
      "evidence": "EnACT Clinical Data VALIDATES the Use of the LNC Platform",
      "confidence": 0.7
    }
  ],
  "frameworks": [
    {
      "name": "process",
      "slug": null,
      "matchId": "867b65ac-c9bc-4446-90c6-54a200f1189d",
      "evidence": "Sequential flow of clinical outcomes",
      "confidence": 0.8
    }
  ],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}